An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Hack, Nawaz ^a   Fayad, Sarah M ^a,b   Monari, Erin H ^a   Akbar, Umer ^a   Hardwick, Angela ^a   Rodriguez, Ramon L ^a   Malaty, Irene A ^a   Romrell, Janet ^a   Wagle Shukla, Aparna A ^a   McFarland, Nikolaus ^a   Ward, Herbert E ^a,b   Okun, Michael S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; ANTIPARKINSON AGENT; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD EXAMINATION; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; EXPERIENCE; FEMALE; HOEHN AND YAHR SCALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; NURSING HOME; PARKINSON DISEASE; PARKINSONISM; PSYCHOSIS; REGISTER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; COMPLICATION; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; PSYCHOTIC DISORDERS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HEMATOLOGIC TESTS; HUMANS; LEVODOPA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NURSING HOMES; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 84898618698     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091545     Document Type: Article

References (46)

1. Driver JA, Logroscino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72(5): 432-438.
2. Pollak P, Tison F, Rascol O, Destee A, Pere J, et al. (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75(5): 689-695. (Pubitemid 38526677)
3. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE et al. (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27(4): 153-156. (Pubitemid 39121725)
4. Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29(6): 331-337. (Pubitemid 44729944)
5. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J (1998) Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 59 Suppl 3: 3-7. (Pubitemid 28196363)
6. Menza MM, Palermo B, Mark M (1999) Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 11(3): 141-144. (Pubitemid 29420230)
7. Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Pract 24(6): 534-540.
8. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 26 Suppl 3: S42-80.
9. Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, et al. (2012) Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 35(2): 61-66.
10. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68(7): 899-904.
11. Chadda RK, Ramshankar P, Deb KS, Sood M (2013) Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother 4(3): 176-186.
12. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, et al. (2005) Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 66(9): 1090-1096. (Pubitemid 41442273)
13. Fernandez HH (2012) Nonmotor complications of Parkinson disease. Cleve Clin J Med 79 Suppl 2: S14-18.
14. Friedman JH (2013) Parkinson disease psychosis: Update. Behav Neurol 27(4): 469-477.
15. Hindle JV (2013) The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient. J Neural Transm 120(4): 649-653.
16. Rabey JM (2009) Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 4: S105-110.
17. Maher KN, Tan M, Tossell JW, Weisinger B, Gochman P, et al. (2013) Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 23(2): 110-116.
18. Gondim FeA, Costa HA, Taunay TC, de Oliveira GR, Ferreira JM, et al. (2010) Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. Mov Disord 25(10): 1505-1506.
19. Stefanis N, Bozi M, Christodoulou C, Douzenis A, Gasparinatos G, et al. (2010) Isolated delusional syndrome in Parkinson's Disease. Parkinsonism Relat Disord 16(8): 550-552.
20. Michalski LS, Hantsch Bardsley C, Holt DR, Milner JE, Hou SH (2009) Altered mental status in a transplant patient. Amantadine toxicity. Kidney Int 75(2): 243-244.
21. Poewe W (2008) When a Parkinson's disease patient starts to hallucinate. Pract Neurol 8(4): 238-241.
22. Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson's disease. Parkinsonism Relat Disord 15(5): 351-353.
23. Postma JU, Van Tilburg W (1975) Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 23(5): 212-215.
24. Neagoe AD (2013) Delirium with manic and psychotic features associated with amantadine. Gen Hosp Psychiatry 35(6): 680.e687-688.
25. Smith EJ (2008) Amantadine-induced psychosis in a young healthy patient. Am J Psychiatry 165(12): 1613.
26. Goetz CG, Vogel C, Tanner CM, Stebbins GT (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51(3): 811-814. (Pubitemid 28449264)
27. Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, et al. (2013) Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks. Parkinsonism Relat Disord 19(8): 725-731.
28. Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, et al. (2013) High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease. Parkinsonism Relat Disord 19(11): 949-954.
29. Filia SL, Wheelhouse A, Lee SJ, Main M, de Castella A, et al. (2012) Transitioning patients taking clozapine from the public to private/GP shared-care setting: barriers and criteria. Aust N Z J Psychiatry 46(3): 225-231.
30. Hack N, Jicha GA, Abell A, Dean D, Vitek JL, et al. (2012) Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol 72(6): 912-917.
31. Munhoz RP, Espay AJ, Morgante F, Li JY, Teive HA, et al. (2013) Long-duration Parkinson's disease: role of lateralization of motor features. Parkinsonism Relat Disord 19(1): 77-80.
32. Hattori N, Yabe I, Hirata K, Li JY, Teive HA, et al. (2013) Brain regions associated with cognitive impairment in patients with Parkinson disease: quantitative analysis of cerebral blood flow using 123I iodoamphetamine SPECT. Clin Nucl Med 38(5): 315-320.
33. Martínez-Martín P, Hernández B, Ricart J Factors (2013) Determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease. Neurologia.
34. Weerkamp NJ, Zuidema SU, Tissingh G, Poels PJ, Munneke M, et al. (2012) Motor profile and drug treatment of nursing home residents with Parkinson's disease. J Am Geriatr Soc 60(12): 2277-2282.
35. Hassan A, Wu SS, Schmidt P, Malaty IA, Dai YF, et al. (2012) What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study. Parkinsonism Relat Disord 18 Suppl 3: S10-14.
36. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, et al. (2003) Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60(11): 1756-1761. (Pubitemid 36737069)
37. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, et al. (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62(3): 381-388. (Pubitemid 38200847)
38. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55(6): 789-794.
39. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH (2000) Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 12(3): 364-369. (Pubitemid 30665218)
40. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340(10): 757-763.
41. Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, et al. (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40(5): 832-834. (Pubitemid 20159625)
42. Crump K, Boo G, Liew FS, Olivier T, So C, et al. (2011) New Zealand community pharmacists' views of their roles in meeting medicine-related needs for people with mental illness. Res Social Adm Pharm 7(2): 122-133.
43. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21(5): 280-284. (Pubitemid 28491427)
44. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, et al. (2001) Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 16(1): 135-139. (Pubitemid 36041128)
45. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, et al. (1998) Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 13(3): 377-382. (Pubitemid 28221486)
46. Goldman JG, Vaughan CL, Goetz CG (2011) An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother 12(13): 2009-2024.